Indirubin-3′-monoxime (160807-49-8) is a potent GSK-3β inhibitor (IC₅₀=22 nM).¹ Also inhibits CDK1 (IC₅₀=180 nM) and CDK5 (IC₅₀=100 nM).¹ Displays antimitotic properties and induces endoreplication following prophase arrest in HBL-100 cells.² Possesses antiangiogenic activity.³ Indirubin-3′-monoxime attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer’s disease.⁴ Cell permeable.

References/Citations:

1) Leclerc et al. (2001), Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer’s disease. A property common to most cyclin-dependent kinase inhibitors?; J. Biol. Chem., 276 251
2) Damiens et al. (2001), Anti-mitotic properties of indirubin-3′-monoximine, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest; Oncogene, 20 3786
3) Kim et al. (2011), Indirubin-3′-monoxime, a derivative of a chinese antileukemia medicine, inhibits angiogenesis; J. Cell. Biochem., 112 1384
4) Ding et al. (2010), Indirubin-3′-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer’s disease; Neurobiol. Dis., 39 156